drugset / Trial / NCT06447597
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Phase 2/3
Recruiting
104 enrolled
Shanghai Jiaolian Drug Research and Development Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B007 | Monoclonal antibody | — | Subcutaneous |